Cargando…
Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans
Omecamtiv mecarbil (OM) is a promising novel drug for improving cardiac contractility. We tested the therapeutic range of OM and identified previously unrecognized side effects. The Ca(2+) sensitivity of isometric force production (pCa(50)) and force at low Ca(2+) levels increased with OM concentrat...
Autores principales: | Fülöp, Gábor Á., Oláh, Attila, Csipo, Tamas, Kovács, Árpád, Pórszász, Róbert, Veress, Roland, Horváth, Balázs, Nagy, László, Bódi, Beáta, Fagyas, Miklós, Helgadottir, Solveig Lind, Bánhegyi, Viktor, Juhász, Béla, Bombicz, Mariann, Priksz, Daniel, Nanasi, Peter, Merkely, Béla, Édes, István, Csanádi, Zoltán, Papp, Zoltán, Radovits, Tamás, Tóth, Attila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041714/ https://www.ncbi.nlm.nih.gov/pubmed/33844095 http://dx.doi.org/10.1007/s00395-021-00866-8 |
Ejemplares similares
-
Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels
por: Ráduly, Arnold Péter, et al.
Publicado: (2023) -
Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
por: Bánhegyi, Viktor, et al.
Publicado: (2021) -
The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
por: Ráduly, Arnold Péter, et al.
Publicado: (2022) -
Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil
por: Hashem, Shaima, et al.
Publicado: (2017) -
Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)